Table 4.
Clinical features of patients infected with HMPV.
| Factor | Pediatric cases |
Adult cases |
||||
|---|---|---|---|---|---|---|
| URTI (n = 42) | LRTI (n = 161) | p | URTI (n = 77) | LRTI (n = 85) | p | |
| Season* | 0.908 | 0.020 | ||||
| 2014-2015 | 10 (25.6 %) | 42 (26.1 %) | 14 (18.4 %) | 19 (22.6 %) | ||
| 2015-2016 | 10 (25.6 %) | 44 (27.3 %) | 46 (60.5 %) | 33 (39.3 %) | ||
| 2016 | 1 (2.56 %) | 9 (5.59 %) | 0 (0.00 %) | 0 (0.00 %) | ||
| 2016-2017 | 18 (46.2 %) | 66 (41.0 %) | 16 (21.1 %) | 32 (38.1 %) | ||
| Age | 2.18 [0.88;6.41] | 1.17 [0.49;2.61] | 0.011 | 66.8 [53.7;77.1] | 74.7 [61.3;82.8] | 0.001 |
| Age group | 0.001 | 0.031 | ||||
| 0-2 years old | 19 (45.2 %) | 95 (59.0 %) | 0 (0.00 %) | 0 (0.00 %) | ||
| 2-5 years old | 10 (23.8 %) | 52 (32.3 %) | 0 (0.00 %) | 0 (0.00 %) | ||
| 5-15 years old | 11 (26.2 %) | 14 (8.70 %) | 0 (0.00 %) | 0 (0.00 %) | ||
| 15-64 years old | 2 (4.76 %) | 0 (0.00 %) | 34 (43.6%) | 23 (27.4%) | ||
| >64 years old | 0 (0.00 %) | 0 (0.00 %) | 44 (56.4%) | 61 (72.6%) | ||
| Sex | 1.000 | 0.197 | ||||
| Female | 18 (42.9 %) | 67 (41.6 %) | 45 (58.4 %) | 40 (47.1 %) | ||
| Male | 24 (57.1 %) | 94 (58.4%) | 32 (41.6%) | 45 (52.9 %) | ||
| Subgenotype | 0.763 | 0.052 | ||||
| A/B | 0 (0.00 %) | 0 (0.00 %) | 0 (0.00 %) | 1 (1.18 %) | ||
| A2 | 24 (57.1 %) | 83 (51.6 %) | 37 (48.1 %) | 46 (54.1 %) | ||
| B1 | 11 (26.2 %) | 44 (27.3 %) | 17 (22.1 %) | 26 (30.6 %) | ||
| B2 | 7 (16.7 %) | 34 (21.1 %) | 23 (29.9 %) | 12 (14.1 %) | ||
| Sublineage | 0.032 | 0.246 | ||||
| A2a | 5 (11.9%) | 2 (1.2%) | 1 (1.3 %) | 2 (2.4 %) | ||
| A2b | 6 (14.3%) | 14 (8.7%) | 7 (9.1 %) | 7 (8.3 %) | ||
| A2c | 13 (31.0%) | 67 (41.6 %) | 29 (37.7 %) | 37 (44.0 %) | ||
| B1 | 11 (26.2) | 44 (27.3%) | 17 (22.1%) | 26 (31.0%) | ||
| B2a | 0 (0.00 %) | 5 (3.1%) | 3 (3.9 %) | 2 (2.4 %) | ||
| B2b | 7 (16.7%) | 29 (18.0%) | 20 (26.0 %) | 10 (11.9%) | ||
| Duplication | 0.768 | 0.048 | ||||
| 111 | 1 (2.4 %) | 5 (3.1%) | 1 (1.3 %) | 6 (7.1 %) | ||
| 180 | 6 (14.3%) | 16 (9.9 %) | 7 (9.1 %) | 15 (17.6 %) | ||
| no | 35 (83.3%) | 140 (87.0%) | 69 (89.6%) | 64 (75.3%) | ||
| Comorbidities | 0.046 | 0.937 | ||||
| Yes | 13 (31.0 %) | 80 (49.7 %) | 63 (81.8 %) | 71 (83.5 %) | ||
| Non | 29 (69.0 %) | 81 (50.3 %) | 14 (18.2 %) | 14 (16.5 %) | ||
| Respiratory comorbidities | <0.001 | 0.799 | ||||
| Asthma | 1 (2.38 %) | 32 (19.9 %) | 0 (0.00 %) | 0 (0.00 %) | ||
| Pneumopathy | 0 (0.00 %) | 20 (12.42%) | 0 (0.00 %) | 0 (0.00 %) | ||
| EPOC | 0 (0.00 %) | 0 (0.00 %) | 15 (19.5 %) | 19 (22.4 %) | ||
| Non | 41 (97.6 %) | 109 (67.7 %) | 62 (80.5 %) | 66 (77.6 %) | ||
| Cardiopathy | 0.532 | <0.001 | ||||
| Yes | 2 (4.76 %) | 14 (8.70 %) | 11 (14.3 %) | 35 (41.2 %) | ||
| Non | 40 (95.2 %) | 147 (91.3 %) | 66 (85.7 %) | 50 (58.8 %) | ||
| Oncohematology | 0.276 | 0.022 | ||||
| Yes | 4 (9.52 %) | 8 (4.97 %) | 31 (40.3 %) | 19 (22.4 %) | ||
| Non | 38 (90.5 %) | 153 (95.0 %) | 46 (59.7 %) | 66 (77.6 %) | ||
| Immunodepression | 0.008 | 0.203 | ||||
| Immunodeficiency | 1 (2.38 %) | 2 (1.24 %) | 23 (29.9 %) | 17 (20.0 %) | ||
| TPH | 3 (7.14 %) | 0 (0.00 %) | 0 (0.00 %) | 0 (0.00 %) | ||
| Non | 38 (90.5 %) | 159 (98.8 %) | 54 (70.1 %) | 68 (80.0 %) | ||
| Diabetes mellitus | . | 0.114 | ||||
| Yes | 0 (0.00 %) | 0 (0.00 %) | 12 (15.6 %) | 23 (27.1 %) | ||
| Non | 42 (100 %) | 161 (100 %) | 65 (84.4 %) | 62 (72.9 %) | ||
| Prematurity | 0.422 | . | ||||
| Yes | 3 (7.14 %) | 21 (13.0 %) | 0 (0.00 %) | 0 (0.00 %) | ||
| Non | 39 (92.9 %) | 140 (87.0 %) | 77 (100 %) | 85 (100 %) | ||
| Chronic kidney disease | . | 0.221 | ||||
| Yes | 0 (0.00 %) | 0 (0.00 %) | 9 (11.7 %) | 17 (20.0 %) | ||
| Non | 42 (100 %) | 161 (100 %) | 68 (88.3 %) | 68 (80.0 %) | ||
| Bacteria co-infection | 0.244 | 0.005 | ||||
| Yes | 4 (9.52 %) | 7 (4.35 %) | 10 (13.0 %) | 28 (32.9 %) | ||
| Non | 38 (90.5 %) | 154 (95.7 %) | 67 (87.0 %) | 57 (67.1 %) | ||
| Viral co-infection | 0.384 | 1000 | ||||
| Yes | 11 (26.2 %) | 30 (18.6 %) | 5 (6.49 %) | 5 (5.88 %) | ||
| Non | 31 (73.8 %) | 131 (81.4 %) | 72 (93.5 %) | 80 (94.1 %) | ||
| Antibiotic | <0.001 | <0.001 | ||||
| Yes | 7 (16.7 %) | 85 (52.8 %) | 42 (54.5 %) | 79 (92.9 %) | ||
| Non | 35 (83.3 %) | 76 (47.2 %) | 35 (45.5 %) | 6 (7.06 %) | ||
| Duplication vs the rest | 0.743 | 0.018 | ||||
| A2c w/ duplication | 7 (22.6 %) | 21 (17.9 %) | 8 (13.3 %) | 21 (36.2 %) | ||
| Other types | 24 (77.4 %) | 96 (82.1 %) | 69 (86.7 %) | 64 (63.8 %) | ||
| A2c sublineage | 0.202 | 0.034 | ||||
| A2c w/ duplication | 7 (53.8 %) | 21 (31.3 %) | 8 (10.4 %) | 21 (24.7 %) | ||
| A2c w/o duplication | 6 (46.2 %) | 46 (68.7 %) | 21 (89.6 %) | 16 (75.3 %) | ||